Filgrastim-ayow (Releuko)
Optional dilutionFull monograph review pending
U.S. label preparation
Releuko · Optional dilution
- Preparation
- For IV dilution use the 300 mcg/mL vial. Dilute with 5% dextrose to no less than 5 mcg/mL. At 5 to 15 mcg/mL add human albumin to a final concentration of 2 mg/mL. Saline can cause precipitation.
- Administration and handling
- The prefilled syringe is for subcutaneous administration. Select the IV infusion schedule for the indication.
Product and source details
Amneal Pharmaceuticals LLC · BLA761082
Product NDC: 70121-1569, 70121-1571
SPL effective 2025-04-24 | SPL version 28. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.